Quantum BioPharma Ltd. is a biopharmaceutical company developing therapies for brain and inflammatory disorders. The company's primary business segment focuses on neurodegenerative diseases, specifically through its investigational drug candidate Lucid-MS, a patented neuroprotective compound designed to address demyelination in multiple sclerosis. A second segment involves consumer health products, including unbuzzd™, a rapid alcohol detoxification beverage sold in the United States through retail channels and e-commerce platforms. The company also maintains a segment for Bitcoin and cryptocurrency investments. Quantum BioPharma was formerly known as FSD Pharma Inc. and was originally formed in 1998 through the amalgamation of several entities, including Olympic ROM World Inc. and Century Financial Capital Group Inc. The company changed its name to Quantum BioPharma Ltd. in August 2024. Its products target patients with multiple sclerosis and other neurodegenerative conditions, as well as consumers seeking post-alcohol recovery solutions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage quantumbiopharma.com
Sector Healthcare IR page quantumbiopharma.com/investors
Tags
neurodegenerative disorders, multiple sclerosis, alcohol detoxification, functional beverages, neuroprotection, myelin degradation, cryptocurrency investments, Lucid-MS, unbuzzd™, Celly U.S., FSD Pharma Inc., Olympic ROM World Inc., Century Financial Capital Group Inc., Dunberry Graphic Associates Ltd.
Press page —

Metrics

Valuation  
Market cap $ 11.829M
Market cap (USD) $ 11.829M
P/E -0.44
PEG —
P/BV 1.21
P/S 20.79
P/OCF -1.44
P/FCF -1.44
Dividend yield —
Turnover / mcap —
Returns  
ROE -336.8%
ROI -380.7%
ROIC -166.9%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue — — 568.919K 183.037K — — 194.723K —
Net profit -26.175M -14.203M -17.902M -23.607M -35.285M -31.8M -39.394M -17.367M
Free cash flow -8.237M -6.876M -10.827M -28.447M -21.246M — -14.21M -17.223M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 7.3 3.68 0.92 0.79 1.03 1.56 0.06 0.21
Price performance 12m 0.98 3 0.17 -0.24 -0.34 24.41 -0.7 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) — 17.5M 35.3M 17M 2.76M 6M —
Income detail
Research and development expense (USD) 0.00 7.83M 6.33M 6.91M 3.86M 6.08M 2.76M
↳ 5y CAGR -18.8%
Reported Mar 31, 2022 Apr 2, 2024 Apr 2, 2024 Apr 2, 2024 Apr 2, 2024 Mar 28, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026.

As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.

Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026.

TORONTO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the results of its annual general and special meeting of shareholders, held on Tuesday, November 10, 2026 in person at 1 Adelaide Street East, Suite 801, Toronto, ON M5C 2V9 (“AGSM”), and the closing on November 9, 2026 of a non-brokered private placement of 26 Class A Multiple Voting Shares (as defined below) (the “Offering”).

Shareholders represented in person or by proxy at the AGSM held 42 class A multiple voting shares (the “Class A Multiple Voting Shares”) and 4,549,222 class B subordinate voting shares (the “Class B Subordinate Voting Shares”), representing 100% and 53.721%, respectively, of the issued and outstanding shares of those classes as of September 28, 2026, the record date for the AGSM (the “Record Date”). Each Class A Multiple Voting Share carries 276,660 votes on all matters on which it is entitled to vote.

For more information visit: www.quantumbiopharma.com under the page Quantum vs Banks.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity.

Prompts

Quantum Biopharma Ltd. (ticker QNTM), listed in United States.

Company History

Date Change Detail
Aug 16, 2024 Renamed FSD PHARMA INC. → QUANTUM BIOPHARMA LTD.
Dec 31, 2020 Reporting currency Its US reports are in USD instead of CAD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.
— Former tickers HUGE

ETFs Holding Quantum Biopharma Ltd.

ETF Weight in ETF Shares Market value As of
PSIL 1.64% 391,932 $ 623.172K Nov 17, 2026